BNP Paribas downgraded shares of AstraZeneca plc (LON:AZN) to a neutral rating in a research report released on Wednesday morning. BNP Paribas currently has GBX 5,200 ($69.26) target price on the biopharmaceutical company’s stock.

AZN has been the subject of a number of other reports. Morgan Stanley boosted their price objective on AstraZeneca plc from GBX 5,000 ($66.60) to GBX 5,800 ($77.25) and gave the stock an overweight rating in a report on Friday, August 19th. Goldman Sachs Group Inc. set a GBX 4,000 ($53.28) price objective on AstraZeneca plc and gave the stock a sell rating in a report on Tuesday, September 6th. Societe Generale set a GBX 7,000 ($93.23) price objective on AstraZeneca plc and gave the stock a buy rating in a report on Thursday, September 8th. JPMorgan Chase & Co. reissued a neutral rating and set a GBX 4,900 ($65.26) price objective on shares of AstraZeneca plc in a report on Tuesday, August 23rd. Finally, Deutsche Bank AG reaffirmed a buy rating and issued a GBX 5,600 ($74.59) target price on shares of AstraZeneca plc in a report on Friday, June 24th. Five equities research analysts have rated the stock with a sell rating, fourteen have issued a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. AstraZeneca plc presently has an average rating of Hold and an average price target of GBX 4,926.80 ($65.62).

AstraZeneca plc (LON:AZN) opened at 5122.00 on Wednesday. The company’s market cap is GBX 64.79 billion. AstraZeneca plc has a 1-year low of GBX 3,680.00 and a 1-year high of GBX 5,505.00. The firm’s 50-day moving average price is GBX 5,017.86 and its 200-day moving average price is GBX 4,330.50.

The business also recently disclosed a dividend, which was paid on Monday, September 12th. Shareholders of record on Thursday, August 11th were issued a GBX 68.70 ($0.92) dividend. The ex-dividend date of this dividend was Thursday, August 11th. This represents a yield of 1.37%.

AstraZeneca plc Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with Analyst Ratings Network's FREE daily email newsletter.